Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Tebas

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Anales De Medicina Interna (Madrid, Spain : 1984)|October 1, 1993
[Fever and recurrent bacteremia as presentation form of secondary aortoenteric fistula]J A Arzuaga Torre, P Tebas Medrano, A Simal Antón, et al.
Cytometry|June 15, 1996
Natural killer cell proliferation and renal disease: a functional and phenotypic studyJ A Vargas, J C Gea-Banacloche, S Ramon y Cajal, et al.
AIDS (London, England)|January 12, 2001
Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patientsX J Zhou, D V Havlir, D D Richman, et al.
HIV Medicine|January 8, 2009
Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular diseaseG Guaraldi, P Ventura, E Garlassi, et al.
The Journal of Antimicrobial Chemotherapy|March 21, 2009
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110P Tebas, J Zhang, R Hafner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 1999
Insulin resistance in HIV protease inhibitor-associated diabetesK E Yarasheski, P Tebas, C Sigmund, et al.
JAMA|January 14, 2000
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimensD V Havlir, N S Hellmann, C J Petropoulos, et al.
HIV Medicine|April 27, 2017
Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxisH C Koenig, K Mounzer, G W Daughtridge, et al.
JAMA|July 13, 2001
Prevalence and predictive value of intermittent viremia with combination hiv therapyD V Havlir, R Bassett, D Levitan, et al.
The New England Journal of Medicine|October 29, 1998
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 TeamD V Havlir, I C Marschner, M S Hirsch, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Anales De Medicina Interna (Madrid, Spain : 1984)|October 1, 1993
[Fever and recurrent bacteremia as presentation form of secondary aortoenteric fistula]J A Arzuaga Torre, P Tebas Medrano, A Simal Antón, et al.
Cytometry|June 15, 1996
Natural killer cell proliferation and renal disease: a functional and phenotypic studyJ A Vargas, J C Gea-Banacloche, S Ramon y Cajal, et al.
AIDS (London, England)|January 12, 2001
Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patientsX J Zhou, D V Havlir, D D Richman, et al.
HIV Medicine|January 8, 2009
Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular diseaseG Guaraldi, P Ventura, E Garlassi, et al.
The Journal of Antimicrobial Chemotherapy|March 21, 2009
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110P Tebas, J Zhang, R Hafner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 1999
Insulin resistance in HIV protease inhibitor-associated diabetesK E Yarasheski, P Tebas, C Sigmund, et al.
JAMA|January 14, 2000
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimensD V Havlir, N S Hellmann, C J Petropoulos, et al.
HIV Medicine|April 27, 2017
Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxisH C Koenig, K Mounzer, G W Daughtridge, et al.
JAMA|July 13, 2001
Prevalence and predictive value of intermittent viremia with combination hiv therapyD V Havlir, R Bassett, D Levitan, et al.
The New England Journal of Medicine|October 29, 1998
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 TeamD V Havlir, I C Marschner, M S Hirsch, et al.
Pageof 5